Kiran Mazumdar Shaw is considered a pioneer in her field for building a phenomenal pharma and research business. Not long ago, Biocon Biologics became the only Indian company to provide affordable access to three biosimilar drugs to the patients in America. Shaw hopes to use funds to funnel more investments into research. “This capital injection by Goldman Sachs will enable us to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.”